Evidence map›Paper›PMID 40888039›Full record

ArticleNeuro-oncology2025

Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.

Nicholas S Cho, Viên Lam Le, Ashley Teraishi, Vicki Liu, Francesco Sanvito, Donatello Telesca, Masanori Nakajo, Chencai Wang, Sonoko Oshima, Blaine S C Eldred and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nicholas S ChoMedical Scientist Training Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-8686-0575
Viên Lam LeDepartment of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-2933-332X
Ashley TeraishiDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0009-0004-3442-8109
Vicki LiuDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Francesco SanvitoDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-3379-9958
Donatello TelescaDepartment of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA.
Masanori NakajoDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Chencai WangDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Sonoko OshimaDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-1453-3807
Blaine S C EldredDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Jingwen YaoDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Phioanh L NghiemphuDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-4064-6079
Noriko SalamonDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-3520-9467
Timothy F CloughesyDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Albert LaiDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-7265-2986
Benjamin M EllingsonDepartment of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-2764-6640

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANG LI · 2017 to 2026
$25.2M
UCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Olujimi A Ajijola, David Wayne Dawson · 2024 to 2026
$5.3M
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
Molecular MR-PET to characterize malignant transformation and identify therapeutic vulnerabilities in human IDH-mutant gliomasF30CA284809 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHO, NICHOLAS S. · 2023 to 2025
$136k
Department of Defense Congressionally Directed Medical Research Programs CA220732NCI NIH HHS F30 CA284809NCI NIH HHS F30CA284809NCI NIH HHS P50 CA211015NCI NIH HHS P50CA211015NCI NIH HHS R01 CA270027NCI NIH HHS R01CA270027NCI NIH HHS R01 CA279984NCI NIH HHS R01CA279984NIGMS NIH HHS T32 GM008042NIGMS NIH HHS T32GM008042NIGMS NIH HHS T32 GM152342NIGMS NIH HHS T32GM152342NIH HHS
6 · The paper itself

Abstract

backgroundThis study explored MRI characteristics at the time of tumor progression to study pathologically confirmed MT in IDHm 1p/19q-intact astrocytomas (IDHm-A) and IDHm 1p/19q-co-deleted oligodendrogliomas (IDHm-O).

methodsN = 64 patients with initial pathological grade 2 IDH-mutant glioma diagnosis who underwent repeated tissue sampling and were classified as pathologically confirmed MT (n = 35) or non-MT (n = 29) with available presurgical anatomical (n = 64), diffusion-weighted (n = 61), and dynamic susceptibility contrast perfusion MRI (n = 53) were retrospectively studied. Measurable contrast enhancement (> 1000 mm3), tumor volume, tumor growth rate, sphericity, median apparent diffusion coefficient (ADC), and normalized relative cerebral blood volume (nrCBV) were compared between MT vs non-MT IDHm-A and IDHm-O.

results81% of contrast-enhancing IDHm-A and 100% of contrast-enhancing IDHm-O demonstrated MT, while 41% of IDHm-A and 62% IDHm-O exhibited both nonenhancing tumor progression and MT. Tumor volumes were significantly larger in patients with MT compared to non-MT groups for IDHm-A (P = .02) and IDHm-O (P = .04). T2/FLAIR tumor volume growth rate was significantly higher (P = .003), nrCBV was significantly higher (P = .002), and ADC trended lower (P = .06) in MT vs non-MT IDHm-A. There were no significant differences in growth rate, ADC, nrCBV, or sphericity when comparing MT vs non-MT IDHm-O (P > .05).

conclusionsMany MT IDHm gliomas remain nonenhancing. Growth rate, diffusion, and perfusion MRI show differences between MT and non-MT in IDHm-A but not IDHm-O, which may reflect the different tumor biology of these IDHm molecular subtypes and their need for separate imaging biomarkers. Tumor volumes can help determine MT for both IDHm-A and IDHm-O.

Indexed as

Brain NeoplasmsCell Transformation, NeoplasticGliomaIsocitrate DehydrogenaseMagnetic Resonance ImagingMutationAdultAgedDiffusion Magnetic Resonance ImagingDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisIsocitrate DehydrogenaseGliomaIDH-mutant astrocytomaIDH-mutant oligodendrogliomamalignant transformationMRI

Identifiers

PMID40888039
PMCPMC12916721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.